Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.22 USD
-0.04 (-1.77%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $2.24 +0.02 (0.90%) 7:18 PM ET
2-Buy of 5 2
D Value C Growth F Momentum D VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Bottom 42% (147 out of 252)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.50 | 1.52 | 9.99 |
Current Quarter Estimate | -0.15 | -2.04 | 60.00 |
Year Ago Quarter Estimate | -0.42 | -0.59 | 52.54 |
Next Quarter Estimate | -0.12 | -2.00 | 61.00 |
Next Year Estimate | -0.75 | 6.92 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 67.09 | 10.10 | 17.08 |
Next Year | -44.23 | 13.20 | 8.00 |
Last 5 Years | NA | 5.90 | 8.10 |
Next 5 Years | NA | 22.10 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | 2.16 | 1.73 |
Price/Cash Flow (MRFY) | NA | 8.52 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | NA | -19.76% |
Return on Equity (TTM) | -109.21% | -75.03% |
Debt to Equity (MRQ) | NA | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.